+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

China Vaccine Market & Doses Forecast By Sector (Private, Public), Disease Type, Products, Company

  • ID: 4876820
  • Report
  • December 2019
  • Region: China
  • 289 pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Liaoning Chengda Co Ltd
  • MORE
Vaccines are developed to address the public health needs. In China, vaccines are available through the government programmed called “Expanded Program on Immunization” at free for all children up to 14 years of age. However private sector vaccines such as Rabies Vaccine, Influenza Vaccine and Haemophilus Influenza Type B vaccine are also available in China but are usually paid for out-of-pocket as these are neither include in government EPI program nor government health insurance schemes. China Vaccine Market has great potential due to its vast population; so, its market size is projected to cross over US$ 9 Billion by 2025.

China vaccine market is divided into public and private vaccine market. Public market is classified by Category 1 whereas and Private vaccines included in Category 2. Vaccines in the public market are regulated by PRC government and generally given free of cost by provincial CDC whereas private vaccine market is dominating by private vaccine companies. As a result, private vaccines prices are higher. China vaccine market has faced several scandals in past couple of years which certainly hinder the vaccine market growth.

This report titled “China Vaccine Market & Doses Forecast By Sector (Private, Public), Disease Type (Meningococcal Meningitis, Pneumococcal, DTP, Ebola, Rabies, Others), Products (MCV4, MPSV4, MCV2-Hib, MCV2, MPSV2 and Men A, PCV13, PPV23, Others), Company (Sinopharm Group, Sinovac Biotech, Beijing Tiantan Biological Products Corp Ltd, Chongqing Zhifei Biological Products Co Ltd, Hualan Biological Engineering Inc, Liaoning Chengda Co Ltd, Walvax Biotechnology Co Ltd)” provides a complete analysis of China Vaccine Market.

Sectors - Vaccine Market & Doses in China
  • Public
  • Private
Disease Type Market - Meningococcal Meningitis, Pneumococcal and DTP Vaccine Market has significant Market Share in China Vaccine Market

On the basis of disease type, Meningococcal meningitis, Pneumococcal and DTP Vaccine market is expected to control major portion of China vaccine market. Vaccine market in China is segmented into Meningococcal meningitis, Pneumococcal, DTP, Ebola, Rabies & Others.

Products - PCV13 Drives Vaccine Market in China

In terms of products, PCV13 hold the maximum share of the China vaccine market. It is predicted that PCV13 will maintain their leading place during the forecasting period as well. Products included in this report are as follows:
  • MCV4
  • MPSV4
  • MCV2-Hib
  • MCV2
  • MPSV2 and Men A
  • PCV13
  • PPV23
Public and Private Vaccine Market & Doses

This report provides the detailed analysis of public and private vaccine market in China. Report also provides private and public vaccine doses in China.

Company Analysis

All the companies covered in the report has been covered from the following points
  • Overview
  • Recent Development
  • Vaccine Pipeline
  • Revenue Analysis
Key Company Covered - China Vaccine Market
  • Sinopharm Group (China National Biotec Group Company Limited)
  • Sinovac Biotech, Beijing Tiantan Biological Products Corp Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • Hualan Biological Engineering Inc
  • Liaoning Chengda Co Ltd
  • Walvax Biotechnology Co Ltd
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Liaoning Chengda Co Ltd
  • MORE
1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.1.1 High Quality Vaccines
4.1.2 Growing Number of Aging Population
4.1.3 Increasing Awareness
4.1.4 Increasing Government Expenditure
4.1.5 Affordability of Vaccines
4.2 Challenges
4.2.1 Research and Development Capabilities
4.2.2 Stringent Quality Management System
4.2.3 Long Development Time Frame
4.2.4 Intensive Capital Requirement
4.3 Opportunities
4.3.1 Implementation of Two Child Policy
4.3.2 Improving Vaccine Provision and Access

5. China Vaccine Market
5.1 Public
5.2 Private

6. China Vaccine Doses
6.1 Public
6.2 Private

7. Market Share - China Vaccine Analysis
7.1 By Sectors
7.2 By Vaccine Doses Share
7.3 By Products Type
7.4 By Disease Type

8. Meningococcal Meningitis Vaccine
8.1 Market
8.1.1 Total China
8.1.2 Public
8.1.3 Private
8.2 Vaccine Doses
8.2.1 Total China
8.2.2 Public
8.2.3 Private
8.3 Vaccine Pipeline

9. Pneumococcal Vaccines
9.1 Market
9.2 Doses
9.3 Vaccine Pipeline

10. DTP Vaccine
10.1 Market - DTP Vaccine
10.1.1 DTaP Vaccine
10.1.2 DTcP and Combination Vaccine
10.2 Doses - DTP Vaccine
10.2.1 Public
10.2.2 Private
10.3 Vaccine Pipeline

11. Rabies Vaccine Market

12. Ebola Vaccine
12.1 Market
12.2 Vaccine Pipeline

13. Products Type - China Vaccine Market
13.1 MCV4
13.2 MPSV4
13.3 MCV2-Hib
13.4 MCV2
13.5 MPSV2 and Men A
13.6 PCV13
13.7 PPV23

14. Vaccine Regulatory Authority of China

15. Required and Recommended Vaccinations for China Travel

16. Mergers and Acquisitions

17. Company Analysis
17.1 Sinopharm Group (China National Biotec Group Company Limited)
17.1.1 Overview
17.1.2 Recent Development
17.1.3 Vaccine Pipeline
17.1.4 Revenue Analysis
17.2 Sinovac Biotech, Beijing Tiantan Biological Products Corp Ltd
17.2.1 Overview
17.2.2 Recent Development
17.2.3 Vaccine Pipeline
17.2.4 Revenue Analysis
17.3 Chongqing Zhifei Biological Products Co Ltd
17.3.1 Overview
17.3.2 Recent Development
17.3.3 Vaccine Pipeline
17.3.4 Revenue Analysis
17.4 Hualan Biological Engineering Inc.
17.4.1 Overview
17.4.2 Recent Development
17.4.3 Revenue Analysis
17.5 Liaoning Chengda Co. Ltd.
17.5.1 Overview
17.5.2 Recent Development
17.5.3 Revenue Analysis
17.6 Walvax Biotechnology Co. Ltd.
17.6.1 Overview
17.6.2 Recent Development
17.6.3 Vaccine Pipeline
17.6.4 Revenue Analysis

List of Figures:
Figure-01: China Vaccine Market in (Million US$), 2018 & 2025
Figure-02: China - Private Vaccine Market Growing Segment in (Million US$), 2018 - 2025
Figure-03: China - Vaccine Market in (Million US$) 2014 - 2018
Figure-04: China - Forecast for Vaccine Market in (Million US$) 2019 - 2025
Figure-05: China - Public Vaccine Market (Million US$) 2014 - 2018
Figure-06: China - Forecast for Public Vaccine Market in (Million US$) 2019 - 2025.
Figure-07: China - Private Vaccine Market in (Million US$) 2014 - 2018
Figure-08: China - Forecast for Private Vaccine Market in (Million US$) 2019 - 2025
Figure-09: China Vaccine Doses in (Million), 2014 - 2018
Figure-10: China - Forecast for Vaccine Doses in (Million), 2019 - 2025
Figure-11: China Public Vaccine Doses in (Million ), 2014 - 2018
Figure-12: China - Forecast for Public Vaccine Doses in (Million), 2019 - 2025
Figure-13: China Private Vaccine Doses in (Million ), 2014 - 2018
Figure-14: China - Forecast for Private Vaccine Doses in (Million), 2019 - 2025
Figure-15: China - Vaccine Market Share by Sectors in (Percent), 2014 - 2018
Figure-16: China - Forecast Vaccine Market Share by Sectors in (Percent), 2019 - 2025
Figure-17: China - Vaccine Market Share by Doses in (Percent), 2014 - 2018,
Figure-18: China - Forecast for Vaccine Market Share by Doses in (Percent), 2019 - 2025
Figure-19: China - Meningococcal Meningitis Vaccine Market (Million US$), 2014 - 2018
Figure-20: China - Forecast For Meningococcal Meningitis Vaccine Market (Million US$), 2019- 2025
Figure-21: Public - Meningococcal Meningitis Vaccine Market (Million US$), 2014 - 2018
Figure-22: Public - Forecast for Meningococcal Meningitis Vaccine Market (Million US$), 2019 - 2025
Figure-23: Private - Meningococcal Meningitis Vaccine Market (Million US$), 2014 - 2018
Figure-24: Private - Forecast for Meningococcal Meningitis Vaccine Market (Million US$), 2019 - 2025
Figure-25: China - Meningococcal Meningitis Doses (Million), 2014 - 2018
Figure-26: China - Forecast for Meningococcal Meningitis Doses (Million), 2019 - 2025
Figure-27: Public - Meningococcal Meningitis Doses (Million), 2014 - 2018
Figure-28: Public - Forecast for Meningococcal Meningitis Doses (Millions), 2019 - 2025
Figure-29: Private - Meningococcal Meningitis Doses (Million), 2014 - 2018
Figure-30: Private - Forecast for Meningococcal Meningitis Doses (Millions), 2019 - 2025
Figure-31: China - Pneumococcal Vaccines Market (Million US$), 2014 - 2018
Figure-32: China - Forecast For Pneumococcal Vaccines Market (Million US$), 2019 - 2025
Figure-33: China - Pneumococcal Vaccines Doses (Million), 2014 - 2018
Figure-34: China - Forecast For Pneumococcal Vaccines Doses in Million, 2019 - 2025
Figure-35: China - DTP Vaccine Market (US$ Million), 2014 - 2018
Figure-36: China - Forecast For DTP Vaccine Market in (US$ Million), 2019 - 2025
Figure-37: China - DTaP Vaccines Market in (US$ Million), 2014 - 2018
Figure-38: China - Forecast For DTaP Vaccines in (Million US$) ,2019 - 2025
Figure-39: China - DTcP Vaccine Market in (US$ Million), 2014 - 2018
Figure-40: China - Forecast for DTcP Vaccine Market in (Million US$), 2019 - 2025
Figure-41: China - DTP Vaccine Doses in (Million), 2014 - 2018
Figure-42: China - Forecast For DTP Vaccine Doses in (Million), 2019 - 2025
Figure-43: China - DTP Public Vaccine Doses (in Million), 2014 - 2018
Figure-44: China - Forecast for DTP Public Vaccine Doses (in Million), 2019 - 2025
Figure-45: China - DTP Private Vaccine Doses in (Million), 2014 - 2018
Figure-46: China - Forecast for DTP Private Vaccine Doses in (Million), 2019 - 2025
Figure-47: China - Rabies Vaccine Market in (Million US$), 2014 - 2018
Figure-48: China - Forecast For Rabies Vaccine Market in (Million US$) , 2019 - 2025
Figure-49: China - Ebola Vaccine Market in (Million US$), 2018 - 2025
Figure-50: China - Forecast for MCV4 Vaccine Market in (Million US$), 2020 - 2025
Figure-51: China - MPSV4 Vaccine Market in (Million US$), 2017 - 2018
Figure-52: China - Forecast For MPSV4 Vaccine Market in (Million US$), 2019 - 2025
Figure-53: China - MCV2-Hib Vaccine Market in (Million US$), 2017 - 2018
Figure-54: China - Forecast For MCV2-Hib Vaccine Market in (Million US$), 2019 - 2025
Figure-55: China - MCV2 Vaccine Market in (Million US$), 2017 - 2018
Figure-56: China - Forecast For MCV2 Vaccine Market in (Million US$), 2019 - 2025
Figure-58: China - MPSV2 and Men A Vaccine Market in (Million US$), 2017 - 2018
Figure-59: China - Forecast For MPSV2 and Men A Vaccine Market in (Million US$), 2019 - 2025
Figure-60: China - PCV13 Vaccine Market in (Million US$), 2017 - 2018
Figure-61: China - Forecast for PCV13 Vaccine Market in (Million US$), 2019 - 2025
Figure-62: China - PPV23 Vaccine Market in (Million US$), 2017 - 2018
Figure-63: China - Forecast For PPV23 Vaccine Market in (Million US$), 2019 - 2025
Figure-64: Global - Sinopharm Group Revenue in (Million US$) , 2014 - 2018
Figure-65: Global - Forecast For Sinopharm Group Revenue (Million US$), 2019 - 2025
Figure-66: Global -Sinovac Biotech Revenue in (Million US$) 2014 - 2018
Figure-67: Global - Forecast For Sinovac Biotech Revenue in (Million US$), 2019 - 2025
Figure-68: Global -Chongqing Zhifei Revenue in (US$ Million), 2014 - 2018
Figure-69: Global - Forecast For Chongqing Zhifei Revenue in (Million US$), 2019 - 2025
Figure-70: Global - Hualan Biological in Revenue (Million US$), 2014 - 2018
Figure-71: Global - Forecast For Hualan Biological Revenue in (Million US$), 2019 - 2025
Figure-72: Global - Liaoning Chengda Revenue in (Million US$), 2014 - 2018
Figure-73: Global- Forecast For Liaoning Chengda Revenue in (Million US$), 2019 - 2025
Figure-74: Global - Walvax Biotechnology Revenue (Million US$), 2014 - 2018
Figure-75: Global - Forecast For Walvax Biotechnology Revenue in (Million US$), 2019 - 2025

List of Tables:
Table-01: China - Vaccine Market Share by Products in (Percent), 2017 - 2018
Table-02: China - Forecast for Vaccine Market Share by Products in (Percent), 2019 - 2025
Table-03: China - Vaccine Market Share by Diseases in (Percent), 2014 - 2018
Table-04: China - Forecast for Vaccine Market Share by Diseases in (Percent), 2019 - 2025
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Sinopharm Group (China National Biotec Group Company Limited)
  • Sinovac Biotech, Beijing Tiantan Biological Products Corp Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • Hualan Biological Engineering Inc
  • Liaoning Chengda Co Ltd
  • Walvax Biotechnology Co Ltd
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll